TFIIB-related factor 1 (Brf1) modulates the transcription of RNA Pol III genes (polymerase-dependent genes). Upregulation of Pol III genes enhances tRNA and 5S RNA production and increases the translational capacity of cells to promote cell transformation and tumor development. However, the significance of Brf1 overexpression in human breast cancer (HBC) remains to be investigated. Here, we investigate whether Brf1 expression is increased in the samples of HBC, and we explore its molecular mechanism and the significance of Brf1 expression in HBC. Two hundred and eighteen samples of HBC were collected to determine Brf1 expression by cytological and molecular biological approaches. We utilized colocalization, coimmunoprecipitation, and chromatin immunoprecipitation methods to explore the interaction of Brf1 with estrogen receptor alpha (ERa). We determined how Brf1 and ERa modulate Pol III genes. The results indicated that Brf1 is overexpressed in most cases of HBC, which is associated with an ER-positive status. The survival period of the cases with high Brf1 expression is significantly longer than those with low levels of Brf1 after hormone treatment. ERa mediates Brf1 expression. Brf1 and ERa are colocalized in the nucleus. These results indicate an interaction between Brf1 and ERa, which synergistically regulates the transcription of Pol III genes. Inhibition of ERa by its siRNA or tamoxifen reduces cellular levels of Brf1 and Pol III gene expression and decreases the rate of colony formation of breast cancer cells. Together, these studies demonstrate that Brf1 is a good biomarker for the diagnosis and prognosis of HBC. This interaction of Brf1 with ERa and Brf1 itself are potential therapeutic targets for this disease.
TFIIB-related factor 1 (Brf1) modulates the transcription of RNA Pol III genes (polymerase-dependent genes). Upregulation of Pol III genes enhances tRNA and 5S RNA production and increases the translational capacity of cells to promote cell transformation and tumor development. However, the significance of Brf1 overexpression in human breast cancer (HBC) remains to be investigated. Here, we investigate whether Brf1 expression is increased in the samples of HBC, and we explore its molecular mechanism and the significance of Brf1 expression in HBC. Two hundred and eighteen samples of HBC were collected to determine Brf1 expression by cytological and molecular biological approaches. We utilized colocalization, coimmunoprecipitation, and chromatin immunoprecipitation methods to explore the interaction of Brf1 with estrogen receptor alpha (ERa). We determined how Brf1 and ERa modulate Pol III genes. The results indicated that Brf1 is overexpressed in most cases of HBC, which is associated with an ER-positive status. The survival period of the cases with high Brf1 expression is significantly longer than those with low levels of Brf1 after hormone treatment. ERa mediates Brf1 expression. Brf1 and ERa are colocalized in the nucleus. These results indicate an interaction between Brf1 and ERa, which synergistically regulates the transcription of Pol III genes. Inhibition of ERa by its siRNA or tamoxifen reduces cellular levels of Brf1 and Pol III gene expression and decreases the rate of colony formation of breast cancer cells. Together, these studies demonstrate that Brf1 is a good biomarker for the diagnosis and prognosis of HBC. This interaction of Brf1 with ERa and Brf1 itself are potential therapeutic targets for this disease.
Introduction
Breast cancer has become the most common cancer and leading cause of cancer mortality in women in the United States (Siegel et al., 2017) . Approximately 80% cases of human breast cancers (HBCs) are estrogen receptor positive (ER+), and~20% are ERÀ (estrogen receptor negative) (Deandrea et al., 2008; MacMahon, 2006; Suzuki et al., 2008) . This finding implies that ERa may play a critical role in breast cancer Abbreviations Brf1, TFIIB-related factor 1; DFS, disease-free survival; ER, estrogen receptor; HBC, human breast cancer; OS, overall survival; Pol III genes, RNA polymerase III-dependent genes; TFIIIB, transcription factor III B. development. ER+ cases of HBC after hormone treatment by tamoxifen (Tam) have a better prognosis than ERÀ cases. Tam is currently used for the treatment of both early and advanced ER+ breast cancer in women (Jordan, 1993) . Tam is an antagonist of the ER in breast tissue, which competitively binds to the ER, producing a nuclear complex, which leads to a decrease in DNA synthesis and an inhibition of the estrogen effects. Studies have indicated that Tam takes part in the regulation of gene transcription, such as c-Jun and c-Fos (Babu et al., 2013) . Emerging evidence has indicated that alcohol consumption is an established risk factor for breast cancer (Chen et al., 2011; Demark-Wahnefried and Goodwin, 2013; Petr et al., 2004; Seitz et al., 2012; Singletary and Gapstur, 2001) . The relative increase in risk ranges from 5% to 10% (~1 drink/10 g per day) to 40-50% (~3 drinks per day) (Singletary et al., 1995; Watabiki et al., 2000) . Alcohol has been classified as carcinogenic to humans by the International Agency for Research on Cancer (Cogliani et al., 2011; IARC, 2011; Shi and Zhong, 2017) . Therefore, alcohol is also a good reagent to study the mechanism of cell transformation and breast tumor development.
RNA Pol (polymerase) III transcribes a number of noncoding RNA, which include tRNA, 5S rRNA, U6 RNA, 7SL RNA, and 7SK RNA. tRNA and 5S rRNA control the translational and growth capacity of cells (Goodfellow et al., 2006; White, 2004) . Studies have indicated that oncogenic proteins, such as c-Myc, c-Jun, c-Fos, and Ras, increase Pol III gene transcription (Goodfellow et al., 2006; Johnson et al., 2008; Zhang et al., 2011 Zhang et al., , 2013 Zhong and Johnson, 2007; Zhong and Johnson, 2009; Zhong et al., 2011) . In contrast, tumor suppressors, such as BRCA1, p53, PTEN, and pRB, decrease transcription of these genes White, 2004; Woiwode et al., 2008; Zhong et al., 2015) . The capacity of these oncogenic proteins and tumor suppressors to alter Pol III gene transcription results from their ability to regulate transcription factor III B (TFIIIB) complex activity. The TFIIIB complex is composed of Brf1, Bdp1, and TATA box-binding protein (TBP). TBP is an initial and general transcription factor to directly or indirectly regulate RNA Pol I, Pol II, and Pol III gene transcription, whereas Brf1 and Bdp1 specifically regulate transcription of RNA polymerase III-dependent genes (Pol III genes) (Shi and Zhong, 2017; Zhang et al., 2013; Zhong et al., 2013a) . Our studies have demonstrated that alteration of TBP is able to change the cellular level of Bdp1, but not Brf1 (Zhong and Johnson, 2009 ), whereas alcohol-mediated ERa activity affects Brf1, but not TBP (Zhang et al., 2013) . This finding suggests that Brf1 plays a more important role in the transcription of tRNA and 5S rRNA. Studies have indicated that specific tRNA are upregulated in HBC cells as promoters of breast cancer metastasis (Goodarzi et al., 2016) . Increased tRNA i Met within cancer cells drives cell migration and invasion to enhance the metastatic potential in melanoma (Birch et al., 2016) . However, the levels of Brf1 expression in human cancers are not well documented. A recent study indicates that Brf1 is overexpressed in hepatocellular carcinoma (Zhong et al., 2016) . To date, there have been no reports on Brf1 expression in HBC.
Our studies have demonstrated that upregulation of Pol III genes results in increases in cell growth, transformation, and tumor development (Zhang et al., 2011 (Zhang et al., , 2013 Johnson, 2007, 2009; Zhong et al., 2011) . The products of the tRNA and 5S rRNA genes are elevated in both transformed cells and tumor cells and biopsies of human cancer, suggesting that they play a crucial role in tumorigenesis Woiwode et al., 2008; Zhang et al., 2011 Zhang et al., , 2013 Johnson, 2007, 2009; Zhong et al., 2011) . A decrease in Brf1 expression reduces Pol III gene transcription and is sufficient for repressing cell transformation and xenograft tumor formation Woiwode et al., 2008; Zhong et al., 2013a Zhong et al., , 2015 Zhong et al., , 2016 . Alcohol increases Brf1 expression to upregulate Pol III gene transcription in vivo and in vitro (Zhang et al., 2013; Zhong et al., 2011) . Studies have indicated that alcohol administration induces breast tumor formation of alcohol-fed mice (Wang et al., 2012; Wong et al., 2012) . This finding suggests that alcohol-caused deregulation of Pol III genes is associated with mammary tumor development. We reported that alcohol increases Brf1 expression through ERa (Zhang et al., 2013) and that BRCA1 represses alcohol-induced Brf1 expression in ER+ breast cancer lines (Zhong et al., 2015) . However, the levels of Brf1 expression in cases of HBC and the relationship of the levels with a prognosis of HBC patients are unclear.
In this study, we have analyzed 218 cases of HBC. The results indicate that Brf1 is overexpressed in most cases of HBC, which is associated with an ER+ status. HBC cases with high Brf1 expression had a longer survival period than those with lower levels of Brf1. Brf1 and ERa are colocalized in the nucleus, and both interact with each other to mediate Pol III gene transcription. Repression of ERa by the ERa siRNA or tamoxifen decreases the cellular level of Brf1 and reduces the rate of colony formation. These studies show that Brf1 is a new biomarker of HBC diagnosis and prognosis, which will be used as a potential target for HBC therapy.
Materials and methods

Patients and samples
Paraffin-embedded tumor tissue samples were obtained from 218 women diagnosed with breast carcinoma who underwent surgical resection between July 2001 and December 2007 in the Department of Breast and Thyroid Surgery and Department of Pathology at the First Affiliated Hospital of Sun Yat-sen University. We obtained prior patient's consent and approval from the Medical Ethical Committee of the First Affiliated Hospital, Sun Yat-sen University, for use in these clinical materials in this study.
All patients' ages ranged from 24 to 79 (median = 50), including 12 cases of in situ carcinoma (DCIS), 196 cases of invasive ductal carcinoma (IDC), four cases of invasive lobular carcinoma (ILC), and six cases of metastatic breast cancer (MBC). None of the patients received chemotherapy or radiotherapy before surgery. Clinicopathological information, such as age, tumor size, lymph node status, ER, PR, and HER2 status, was obtained by reviewing medical records and pathology reports.
Fresh tumor specimens were obtained from the patients who underwent resection of the primary breast cancer in the Department of Breast and Thyroid Surgery at the First Affiliated Hospital of Sun Yat-Sen University. Representative blocks from both the tumor (T) and tumor adjacent noncancerous tissues (N) from each specimen were stored in liquid nitrogen for RNA and protein extraction. Informed consent was obtained from each patient, and the study was approved by the Institute Research Ethics Committee of Sun Yat-Sen University (ID number: No. [2017] 014). None of the patients had previously received chemotherapy or radiation therapy.
Cell line, reagents, and antibodies
The human breast adenocarcinoma cell line MCF-7 (HTB-22) was from ATCC (Manassas, VA, USA). Cell culture medium (Dulbecco's modified Eagle's medium [DMEM]/F12), OPTI-MEM, Lipofectamine 2000, and TRIzol reagent were from Life Technologies (San Diego, CA, USA). Antibodies against ERa (Clone No.33) were from Novus Biologicals (Littleton, CO, USA). Actin mouse monoclonal antibody (2Q1055, Catalog No.SC-58673) was obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). Mismatch RNA (mm RNA) was described previously (Zhong et al., 2013b) . The Brf1 antibody (Catalog No.A301-228A) was from Bethyl laboratories Inc. (Montgomery, TX, USA). The sequences of the primers and Brf1 and ERa siRNA were described previously in Supplements.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections (4 lm thick) that were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol, and rinsed in 19 PBS, and then antigen retrieval was performed with microwave treatment in 10 mM EDTA buffer (pH 9.0). Immunohistochemistry (IHC) staining was performed using the EnVision TM Kit (DAKO, Hamburg, Denmark) following the manufacturer's instructions. Endogenous peroxidase activity was quenched by 3% hydrogen peroxide for 15 min. The sections were then incubated with rabbit polyclonal anti-human BRF1 antibodies (1 : 200) overnight at 4°C. Next, the tissue sections were sequentially incubated with ready-to-use HRP immunoglobulin (EnVision TM ) for 30 min and then were developed with 3,3 0 -diaminobenzidine (DAB) as a chromogen substrate. The nuclei were counterstained with Meyer's hematoxylin.
The levels of Brf1 immunostaining were evaluated independently by two pathologists who were blinded to the survival outcomes of the participants based on the proportion of positively stained tumor cells (stain area) and the intensity of staining. Staining intensities were scored as 0 (no staining), 1 (weak staining) for light yellow color, 2 (moderate staining) for yellow brown color, and 3 (strong staining) for brown color. The positive tumor cell proportion was scored as 0 (no positive tumor cells), 1 (< 5% positive tumor cells), 2 (5-25% positive tumor cells), 3 (25-50% positive tumor cells), and 4 (> 50% positive tumor cells). A modified immunoreactivity score to evaluate the immunostaining results was performed by multiplying the stain intensity by stain area (staining index, SI) as previously described (Li et al., 2009) . The BRF1 expression levels in breast carcinoma lesions were determined by the SI, which was 0, 1, 2, 3, 4, 6, 9, or 12. An optimal cutoff value was identified as follows: An SI score of > 4 was used to define tumors as high Brf1 expression, and an SI score of ≤ 4 as low.
Western blot analysis
Tissue samples were ground into a powder with liquid nitrogen and lysed in lysis buffer with phosphatase and protease inhibitors. MCF-7 cells were treated with 25 mM ethanol to extract total cell lysates. Protein concentrations of the resultant lysates were measured by the Bradford method using a Fluostar Omega spectrometer (Cell Biology Core Laboratory of University of Southern California Research Center for Liver Diseases, P30 DK048522). Lysates (50 lg of protein) of tissues or cells were separated by SDS/PAGE and subjected to western blot analysis as previously described (Zhong et al., , 2013b . Membranes were probed with specific antibodies against Brf1, ERa, and b-actin as indicated. A Hybond-P membrane was used for protein transfer. Bound primary antibody was visualized using horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, USA) and enhanced chemiluminescence reagents (Cell Signaling Technology, Danvers, MA, USA). All of the experiments were repeated at least three times.
Immunofluorescence
The collected tumors were fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4-lm-thick sections using a microtome. After removing the paraffin wax with xylene, antigens were retrieved with a microwave treatment in 10 mM EDTA buffer (pH 9.0). The tissue sections were blocked with 5% BSA for 1 h at room temperature and were incubated with rabbit polyclonal anti-human BRF1 antibodies (1 : 200) or Mouse monoclonal ERa antibody (1 : 100) overnight at 4°C and then incubated with anti-rabbit IgG FITC or anti-rabbit IgG CY3 (Invitrogen Life Technologies Corporation, Invitrogen, Carlsbad, CA, USA) as secondary antibodies (1 : 4000). Nuclear staining of cells was performed using 4,6-diamidino-2-phenylindole (DAPI, Beyotime Biotechnology, Shanghai, China). The slides were mounted in antifade reagent (Invitrogen Life Technologies Corporation). The photomicrographs were captured using an Olympus BX63 fluorescence microscopy (Germany).
Statistical analysis
The ER, PR, and Her2 results in each sample were obtained from the pathology reports. We attempted to categorize the distribution of the ER and PR percentages in two groups according to the description in the methods. For the ER levels, low expression was 0-25% and high expression was ≥ 25%. For the PR levels, low expression was 0-25% and high expression was ≥ 25%. We categorized the positive or negative status of Her2 according to NCCN Guidelines of Breast Cancer.
All statistical analyses were carried out using the SPSS 22.0 (IBM, Chicago, IL, USA) statistical software package. The chi-square and Fisher's exact tests were used to analyze the relationship between Brf1 expression and clinicopathological or molecular features.
Bivariate correlations between study variables were calculated by Spearman's rank correlation coefficients. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. A P < 0.05 in all cases was considered to be statistically significant.
Results
Brf1 overexpression and its clinical significance in the cases of human breast cancer
Brf1 is a transcription factor, which specifically regulates Pol III gene transcription. The upregulation of Pol III genes is tightly associated with cell transformation and tumor development. However, Brf1 expression in HBC patients was not determined. To explore the levels and significance of Brf1 expression in the HBC cases, we collected 218 samples from HBC patients and performed IHC analysis using a specific antibody against Brf1. Representative staining results are shown in Fig. 1 . Strong Brf1 signals are observed in tumor foci of the HBC tissue compared to the para tissue (around tumor foci; Fig. 1A1,B1 ). In 218 cases, we defined the four types of staining intensity as negative staining (64/218, 29.4%), weak nuclear staining (50/218, 22.9%), moderate staining (42/218, 19.3%), and strong staining (62/218, 28.4%; Fig. 2B ). The difference in Brf1 expression between tumor foci (T; Fig. 2A , upper panels) and adjacent noncancerous tissue (ANT; Fig. 2A , lower panels) is marked. Brf1 primarily accumulates in the nucleus (178/218), in the cytoplasm (8/218), or both (40/218). One hundred and two cases (46.8%) have strong Brf1 staining in lesion tissues with an SI > 4, which is classified as the high Brf1 expression group. The other one hundred and sixteen cases (53.2%) of breast carcinoma include moderate, weak, or negative staining in the lesion tissues with SI ≤ 4, which is classified as low Brf1 expression group. The clinicopathological characteristics of HBC cases are summarized in Table 1 and Table S4 (in supplementary tables). The results indicate that there is not a significant correlation between Brf1 expression and other clinicopathological features, such as patient age, pausimenia, histological type, clinical stage, tumor size, lymph node, and metastasis (Table S4 in supplementary). In contrast, there is a significant correlation between high Brf1 expression and high ER expression (P = 0.012), high PR expression (P = 0.035), or nontriple-negative status (P = 0.012), but not Her2 expression (P = 0.357; Table 1 ). These studies indicate that the levels of Brf1 expression of HBC cases are associated with their hormone statuses.
Relationship between Brf1 expression and prognosis of breast adenocarcinoma patients
We have investigated Brf1 expression levels and the clinical follow-up information for 218 patients of HBC by Kaplan-Meier analysis and log-rank test. The results show that the overall survival (OS) times in patients with low Brf1 expression (118.7 AE 5.4 months, n = 116) are significantly shorter than one in patients with high Brf1 expression (137.5 AE 4.4 months, n = 102, P = 0.004; Fig. 3A, left) . Furthermore, the disease-free survival (DFS) months in the high Brf1 expression group (135.3 AE 5.0 months) are markedly longer than those in the low Brf1 expression group (112.8 AE 6.4 months, P = 0.004; Fig. 3A, right) . These results reveal that patients with high Brf1 expression have better prognosis. In addition, we have also determined the mean survival times in subgroups of patients with different ER status and triple-negative status. The results of Kaplan-Meier analyses indicate that the patients in the low Brf1 expression group with low or negative expression of ER have significantly shorter survival times, compared to those in the high Brf1 expression group, P = 0.009 (Fig. 3B ). There is not a significant difference in the OS or DFS times in the ER high expression subgroup. Similar results, both OS and DFS, are revealed in the cases with high Brf1 expression compared to those with low Brf1 expression in non-triple-negative status (P = 0.005 or P = 0.001; Fig. 3C ). However, TNBC patients (46 cases) do not display this kind of OS feature (Fig. S1 ). The TNBC group (n = 16) with high Brf1 expression reveals shorter DFS period (108 months) when comparing to those (n = 30) with low Brf1 expression (120 months).
Change in cellular level of ERa alters Brf1 expression
To investigate the relationship between ER status and Brf1 expression, we measured the cellular levels of ERa and Brf1 in the biopsies of HBC patients by western blot analysis. The results indicate that the levels of ERa or Brf1 protein in HBC tumor foci are higher than those in ANT (Fig. 4A ). High levels of ERa are accompanied by Brf1 overexpression in the samples from the HBC patients (Fig. 4A ). This implies that ERa may modulate Brf1 expression. To further explore the mechanism of high Brf1 expression with a longer survival period of ER+ cases, we treated the ER+ breast cancer line MCF7 cells with ethanol, which has been classified as a carcinogen to humans. The results indicate that ethanol causes~3-fold increase in ERa and Brf1 mRNA levels (Fig. 4B ,C, left), but also slightly augments their protein levels ( Fig. 4B,C, right) . Next, we transfected MCF7 cells with ERa siRNA, compared to the control RNA [mismatch (mm) RNA]. The results show that ERa siRNA reduces ERa expression and decreases cellular levels of Brf1 mRNA and protein (Fig. 4B,C) . Furthermore, ethanol increases ERa occupancy of the Brf1 promoter (Fig. 4D) . In contrast, ERa siRNA lessens its occupancy on the promoter. These studies demonstrated that ERa indeed modulates Brf1 expression.
Both Brf1 and ERa modulate transcription of RNA Pol III genes
To explore whether there is a synergistic role of ERa and Brf1 in Pol III gene transcription, we performed an ERa and Brf1 colocalization analysis by immunofluorescence staining for the HBC tissues. The results show that both ERa and Brf1 have positive staining in ER+ tumor tissues ( Fig. 5A) . Interestingly, ERa and Brf1 are colocalized in the nuclei of the tumor cells ( Fig. 5B ). This result displays that ERa and Brf1 may interact to modulate Pol III genes. To investigate this interaction, we performed coimmunoprecipitation assay with ERa and Brf1 antibodies. As we can see, the ERa antibody is able to put down Brf1, whereas Brf1 antibody can also precipitate ERa (Fig. 5C,D) . These studies show that the interaction between ERa and Brf1 exists. Further analysis indicates that repression of either ERa or Brf1 by their siRNA decreases tRNA Leu (Fig. 6A,C) and 5S rRNA (Fig. 6B,D) transcription. To identify whether ERa directly modulates Pol III genes, we performed a ChIP assay. The results reveal that ERa occupies the promoters of tRNA Leu and 5S rRNA (Fig. 6E,F) . These studies demonstrate that both ERa and Brf1 modulate Pol III gene transcription.
Alteration of Brf1 and Pol III gene transcription causes cell phenotypic change
The above studies have shown that ER+ cases of HBC with high Brf1 expression display better prognosis. Therefore, we have further determined an underlying mechanism of hormone therapy by Tam, which is a good medicine for ER+ cases of HBC. We treated ER+ breast cancer MCF7 cells with Tam and then determined the alteration of Brf1 expression and Pol III gene transcription. The results indicate that Tam decreases cellular levels of Brf1 mRNA and protein (Fig. 7A,B ). Tam treatment also reduces transcription of tRNA Leu and 5S rRNA (Fig. 7C,D) . Furthermore, we performed a soft agar assay to test whether Tam affects colony formation. The results reveal that Tam treatment decreases the rate of colony formation (Fig. 7E) . Thus, these studies show that the effects of Tam on Brf1 and Pol III genes cause phenotypic changes in colony formation.
Discussion
In the studies, we have presented the mechanistic analysis of ER+ breast cancer and measured the levels of Brf1 expression in 218 cases of HBC for the first time.
The results indicate that Brf1 is overexpressed in most HBC cases. Brf1 is mainly localized in the nuclei of HBC tumor cells. The levels of Brf1 in tumor foci are much higher than those of ANT. The cases of HBC with high Brf1 expression have a longer survival period. There is a significantly different survival period in high Brf1 expression with ER+ and PR+ statuses, compared to ERÀ and PRÀ statuses. Further analysis indicates that alteration of ERa affects Brf1 expression and Pol III gene transcription. ERa and Brf1 are colocalized in nuclei. The interaction of Brf1 with ERa plays an important role in regulating Pol III gene transcription. Tam inhibits the expression of Brf1 and Pol III genes, resulting in reducing the rate of colony formation (Fig. 8) . Brf1 may be used as a new indicator of HBC diagnosis and prognosis. These studies uncover a novel mechanism and the significance of Brf1 overexpression in this disease, which is also a new interpretation of the efficacy on ER+ HBC by Tam treatment.
Overall survival is the period from surgical resection to death, which includes cancer recurrence and metastasis or nature death (noncancer reasons, such as aging and so on); however, DFS is the time from surgical resection to cancer recurrence and metastasis.
The patients of DFS mainly died from cancer. In this study, ER+ and PR+ cases with high Brf1 expression represent most part of non-TNBC patients, who have cells were transfected with mismatch RNA (mm RNA) as a control RNA or ERa siRNA for 48 h and treated with ethanol as described previously (Zhang et al., 2013) . The cell lysates and total RNA were extracted from these cells to determine protein levels of ERa, Brf1, and b-actin by western blot (B and C, right panels). mRNA levels of ERa and Brf1 were measured by RT-PCR (B,C, left panels). (D): ERa occupancy of Brf1 promoter: Chromatin was extracted from ethanol-treated MCF-7 cells to carry out ChIP assay with ERa or histone H3 antibodies, respectively. H3 is used as a control. These results indicate that ERa modulates Brf1 expression.
best outcomes with much late recurrence or metastasis, and longer survival time. For the group with high Brf1 expression, the difference between OS (137.5 months) and DFS (135.3 months) is about 2 months ( Fig. 2A,  green lines) . The group with low Brf1 expression, representing most cases of TNBC, had worse outcomes including earlier cancer recurrence and metastasis. The difference between OS (118.7 months) and DFS (112.8 months) for the group with low Brf1 expression is about 6 months (Fig. 3A, blue lines) . Thus, the period (6 months) between OS and DFS of the patients with low Brf1 expression is longer than the time (2 months) for those with high Brf1 expression. The analysis of clinical information demonstrates that ER+ patients with high Brf1 expression display good prognosis.
Although studies on breast cancer have been well documented, to date, there have still been no reports on the mechanism and significance of Brf1 expression in HBC. Alcohol consumption is consistently associated with the risk of breast cancer (Deandrea et al., 2008; MacMahon, 2006; Suzuki et al., 2008) . Alcohol feeding prompted mammary tumor formation (Wang et al., 2012; Wong et al., 2012) . Our studies have Magnification, up: 2009; down: 10009 . Interaction between Brf1 and ERa: MCF-7 cells were treated with ethanol to extract cell lysates and to perform immunoprecipitation with Brf1 and ERa antibodies, respectively. Western blot analysis indicates that Brf1 antibody is able to put down ERa protein (C), whereas the antibody of ERa can also precipitate Brf1 protein (D). The input samples at C and D were from the ethanol-treated cells. The results reveal the interaction of Brf1 with ERa in ER+ breast cancer cells. . The cells were treated as described above. The levels of Brf1 protein were measured by western blot (B). RT-qPCR was performed to determine the amounts of Brf1 mRNA (A) and pre-tRNA Leu (C) and 5S rRNA transcription (D). The fold changes were calculated by normalizing to the amount of GAPDH mRNA. The bars represent mean AE SE of at least three independent determinations. (E-F): Soft agar assay: MCF-7 cells were transfected with mm RNA, ERa siRNA, or Brf1 siRNA for 48 h, respectively. The cells were seeded in 69 well plates and treated with ethanol (25 mM) and Tam (12.5 lM) as previously described (Zhong et al., 2014) . The cells were analyzed for colony formation in soft agar. Colonies were counted at 2-3 weeks after plating. Values are the means AE SE (n ≥ 3). *P < 0.05 as indicated. demonstrated that alcohol increases Brf1 expression and Pol III gene transcription to facilitate cell transformation and tumor formation (Zhang et al., 2013; Zhong et al., 2011 Zhong et al., , 2016 . BRCA1 is a tumor suppressor (Duncan et al., 1998; Yoshida and Miki, 2004) , which is responsible for repairing damaged DNA (Chen et al., 2011) . Women with an abnormal BRCA1 gene have up to an 80% higher risk of developing breast cancer (Friendenson, 2007) . We determined that restoring BRCA1 in HCC 1937 cells, which is a BRCA1-deficient line, represses Pol III gene transcription (Zhong et al., 2015) . More interestingly, overexpression of BRCA1 in MCF-7 decreases the induction of tRNA Leu and 5S rRNA genes caused by alcohol (Zhong et al., 2015) . Thus, alcohol is a good reagent to explore the underlying mechanism of breast cancer.
As Brf1 specifically regulates tRNA Leu and 5S rRNA gene transcription, it implies that Brf1 may play a critically important role in HBC development. In the present study, the results indicate that ERa modulates Brf1 expression and Pol III gene transcription (Figs 4  and 6 ). Repression of ERa decreases ethanol-caused induction of Brf1 and Pol III genes (Figs 4 and 6) , whereas human sample studies have shown that Brf1 overexpression is significantly linked to ER+ and PR+ statuses of HBC cases (Figs 1 and 4A , Table 1 ). Increase in transcription of Brf1 and Pol III genes promotes tumor formation Zhong et al., 2011) , while high Brf1 expression results in shorter survival period for the patients of hepatocellular carcinoma (Zhong et al., 2016) . However, the HBC cases with low Brf1 show worse prognosis, compared to those with high Brf1 expression ( Fig. 3) . This is because most of the cases with low Brf1 expression were associated with TNBC (triple-negative breast cancer), which were more difficult to treat by hormone therapy, resulting in shorter survival period. In contrast, the HBC cases with high Brf1 expression were at ER+ and PR+ status, and hormone therapy was more effective in these cases. Thus, their prognosis is better than those with low Brf1 expression. Here, our results in vitro (Figs 4 and 6) further demonstrated that ERa positively modulates Brf1 expression and Pol III gene transcription. This supports an idea that the difference in survival periods between high and low Brf1 expression is dependent on ER+ expression and efficacy of hormone treatment, such as Tam.
In clinical practice, Tam was used to treat ER+ HBC cases. The HBC patients with high Brf1 expression are in the ER+ group. After the treatment, these patients revealed better prognosis. This is because Tam represses Brf1 and Pol III gene expression ( Fig. 7) . However, TNBC patients (46 cases) did not display this kind of OS feature (Fig. S1 ). The TNBC group (n = 16) with high Brf1 expression revealed shorter DFS period (108 months) when comparing to those (n = 30) with low Brf1 expression (120 months). This result further proves that high Brf1 expression is associated with better prognosis in ER+ HBC patients. However, as we did not gain enough TNBC cases samples, the result did not display significance (P > 0.05). We will collect additional TNBC case samples to observe this feature. As described above, although this is an unexpected result, it shows the tissue specificity of breast cancer, namely ER+ and PR+. The analysis explains why the cases with low Brf1 expression had worse prognosis.
As~80% of HBC cases are ER+, these cases who received hormone treatment with Tam display a longer survival period and good prognosis (Fig. 3) . Tam is widely used in postmenopausal ER+ women with HBC. However, Tam acts as an estrogen agonist, leading to certain adverse effects. Hot flashes are the most common side effect caused by Tam, which affects up to 80% of women. Hot flashes intolerances lead to a severely decreased quality of life and treatment compliance in patients. Endometrial hyperplasia is another common adverse effect in clinical practice, leading to about a 2.5 times higher risk of developing endometrial cancer (Henry et al., 2008; Jordan, 2014; Osborne, 1998) . Clinically, cases of Tam resistance are met often. Resistance to endocrine therapies is a major issue in recurrent ER+ HBC patients (De Marchi et al., 2016) . Several mechanisms have been connected to endocrine resistance, such as mutation in the ligand-binding domain of the ER (Toy et al., 2013) , enhanced growth factor signaling, altered DNA methylation of specific genes (Graff et al., 1995; Widschwendter and Jones, 2002) , or the dysregulation of metabolic pathways (Wang et al., 2016) . In our study, we discovered a novel mechanism demonstrating that Tam decreases Brf1 expression and Pol III gene transcription (Fig. 7A,B) to inhibit ethanol-promoted colony formation of breast cancer cells (Fig. 7C ). In addition, our study indicates that Brf1 induction is required for ethanol to increase colony formation in soft agar (Fig. 7E) , which supports an idea that ethanol-enhanced Brf1 expression may promote alcoholassociated breast cancer development. The new finding not only raises our mechanism of understanding the disease, but also provides a possible therapy through repressing Brf1 expression. Thus, developing an inhibitor of Brf1, which is a downstream component of ER pathway, is more important to enhance the efficacy of Tam on the HBC patients by repressing Brf1 expression. TNBC refers to any HBC that does not express the ER, PR, or Her2 genes. This property makes it more difficult to treat TNBC patients, as most hormone therapies target one of the three receptors. More interestingly, our studies indicate that low Brf1 expression is significantly associated with the HBC triplenegative status (P = 0.012; Table 1 ), which further suggests that Brf1 expression is strongly associated with ER status. Therefore, a decrease in the cellular level of Brf1 is a new direction as therapy of HBC ER+ patients and the patients with Tam-resistant and/ or triple-negative status.
In summary, we determined that the cases of HBC with high Brf1 expression have a longer survival time and good prognosis. Mechanistic analysis indicates that repression of ERa decreases cellular levels of Brf1 mRNA and protein. The interaction of Brf1 with ERa synergistically regulates Pol III gene transcription. Tam inhibits the expression of Brf1 and Pol III genes and decreases the rate of colony formation, which indicates new implication of the mechanism of Tam treatment for HBC patients. These findings provide a new direction to develop drugs inhibiting Brf1 expression and to increase efficacy of the HBC patients by Tam.
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Kaplan-Meier survival curve and log-rank test analysis of the association between Brf1 expression and THBC patient survival.
